Keyphrases
Therapeutic Target
100%
Multiple Myeloma
100%
Multiple Myeloma Patients
100%
Single-cell RNA Sequencing (scRNA-seq)
100%
Resistance Pathways
100%
Relapsed or Refractory multiple Myeloma
100%
Prolyl Isomerase
80%
Protein Folding
40%
Newly Diagnosed multiple Myeloma
40%
Clinical Trials
20%
Molecular Dynamics
20%
Protease Inhibitors
20%
Tumor
20%
Durable Response
20%
Clinical Endpoints
20%
Tumor Cells
20%
Molecular Pathways
20%
New Targets
20%
Tolerability
20%
Progression-free Survival
20%
Overall Survival
20%
Clinical Cohort
20%
Response Pathways
20%
Cas9 Protein
20%
Resistance Mechanisms
20%
Small Molecule Inhibitors
20%
Mitochondrial Respiration
20%
Lenalidomide
20%
Early Relapse
20%
Ciclosporin
20%
Clonal Proliferation
20%
Hypoxia Tolerance
20%
Bortezomib
20%
Overall Response Rate
20%
Primary Refractory
20%
Malignant Plasma Cells
20%
Treatment-resistant Patients
20%
Relapsed Patients
20%
Induction Regimen
20%
Neoplastic Plasma Cells
20%
Disease Heterogeneity
20%
Daratumumab
20%
Single-arm Clinical Trial
20%
Carfilzomib
20%
CoMMpass
20%
Plasma Cell Disorders
20%
Biochemistry, Genetics and Molecular Biology
Peptidylprolyl Isomerase A
100%
Protein Folding
50%
Clinical Trial
50%
Immunoglobulin Producing Cell
50%
RNA Sequence
50%
Dynamics
25%
Enzyme
25%
Ciclosporin
25%
Normal Human
25%
Proteasome Inhibitor
25%
Small Molecule
25%
Overall Survival
25%
Progression Free Survival
25%
Mitochondrial Respiration
25%
Dexamethasone
25%
Neuroscience
Cyclophilin A
100%
RNA Sequence
50%
Protein Folding
50%
Immunoglobulin Producing Cell
50%
Proteasome Inhibitor
25%
Mitochondrial Respiration
25%
Dexamethasone
25%
Ciclosporin
25%
Bortezomib
25%
Lenalidomide
25%
Daratumumab
25%
Carfilzomib
25%
Medicine and Dentistry
Multiple Myeloma
100%
Cyclophilin A
44%
Clinical Trial
22%
RNA Sequence
22%
Immunoglobulin Producing Cell
22%
Protein Folding
22%
Diseases
22%
Arm
11%
Neoplasm
11%
Hypoxia
11%
Tumor Cell
11%
Dexamethasone
11%
Overall Survival
11%
Cyclosporine
11%
Progression Free Survival
11%
Lenalidomide
11%
Proteasome Inhibitor
11%
Bortezomib
11%
Clinical Endpoint
11%
Mitochondrial Respiration
11%
Daratumumab
11%
Carfilzomib
11%
Immunology and Microbiology
Multiple Myeloma
100%
Single-Cell Sequencing
100%
Protein Folding
22%
RNA Sequence
22%
Immunoglobulin Producing Cell
22%
Ciclosporin
11%
Normal Human
11%
Arm
11%
Tumor Cell
11%
Proteasome
11%
Dynamics
11%
Overall Survival
11%
Dexamethasone
11%
Lenalidomide
11%
Progression Free Survival
11%
Mitochondrial Respiration
11%
Daratumumab
11%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Cyclophilin A
44%
Clinical Trial
22%
Neoplasm
22%
RNA-Sequencing
22%
Diseases
22%
Normal Human
11%
Hypoxia
11%
Proteasome Inhibitor
11%
Tolerability
11%
Dexamethasone
11%
Progression Free Survival
11%
Overall Survival
11%
Ciclosporin
11%
Lenalidomide
11%
Bortezomib
11%
Daratumumab
11%
Carfilzomib
11%